Genetic variation in the bleomycin hydrolase gene and bleonnycin-induced pulmonary toxicity in germ cell cancer patients

Pharmacogenetics and Genomics

Volumn 15, Issue 6, 2005, Pages 399-405

  Nuver, Janine ^a   Holzik, Martijn F Lutke ^a   Van Zweeden, Martine ^a   Hoekstra, Harald J ^a   Meijer, Coby ^a   Suurmeijer, Albert J H ^a   Groen, Harry J M ^a   Hofstra, Robert M ^a   Sluiter, Wim J ^a   Groen, Henk ^a   Sleijfer, Dirk T ^a   Gietema, Jourik A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Bleomycin; Bleomycin hydrolase; Germ cell cancer; Polymorphism; Pulmonary toxicity

Indexed keywords

BLEOMYCIN; BLEOMYCIN HYDROLASE; CREATININE; CYTOTOXIC AGENT;

ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BMH GENE; CANCER CHEMOTHERAPY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EXCRETION; DRUG INACTIVATION; ENZYME ACTIVITY; FATALITY; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GERM CELL TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CLEARANCE; KIDNEY FUNCTION; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG METASTASIS; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PNEUMONIA; POLYMERASE CHAIN REACTION; POLYMORPHIC LOCUS; PRIORITY JOURNAL; PROTEIN DOMAIN; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STATISTICAL SIGNIFICANCE; THORAX RADIOGRAPHY;

EID: 20644437539     PISSN: 17446872     EISSN: None     Source Type: Journal    
DOI: 10.1097/01213011-200506000-00005     Document Type: Article

References (32)

1. Umezawa H, Meaeda K, Takeuchi T, Okami Y. New antibiotics, bleomycin A and B. J Antibiot Ser A 1966; 19:200-209.
2. de Wit R, Stoter G, Kaye SB, Sleijfer DTh, Jones WG, ten Bokkel H, et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 1997; 15:1837-1843.
3. Sleijfer S. Bleomycin-induced pneumonitis. Chest 2001; 120:617-624.
4. Adamson IY, Bowden DH. The pathogenesis of bleomycin-induced pulmonary fibrosis in mice. Am J Pathol 1974; 77:185-197.
5. Van Barneveld PW, Sleijfer DT, vander Mark TW, Mulder NH, Koops HS, Sluiter HJ, et al. Natural course of bleomycin-induced pneumonitis. A follow-up study. Am Rev Respir Dis 1987; 135:48-51.
6. O'Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 2003; 14:91-96.
7. Dearnaley DP, Horwich A, A'Hern R, Nicholls J, Jay G, Hendry WF, et al. Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: long-term follow-up. Eur J Cancer 1991; 27:684-691.
8. Jules-Elysee K, White DA. Bleomycin-induced pulmonary toxicity. Clin Chest Med 1990; 11:1-20.
9. White DA, Stover DE. Severe bleomycin-induced pneumonitis. Clinical features and response to corticosteroids. Chest 1984; 86:723-728.
10. Simpson AB, Paul J, Graham J, Kaye SB. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours. Br J Cancer 1998; 78:1061-1066.
11. Bromme D, Rossi AB, Smeekens SP, Anderson DC, Payan DG. Human bleomycin hydrolase: molecular cloning, sequencing, functional expression, and enzymatic characterization. Biochemistry 1996; 35:6706-6714.
12. Ferrando AA, Velasco G, Campo E, Lopez-Otin C. Cloning and expression analysis of human bleomycin hydrolase, a cysteine proteinase involved in chemotherapy resistance. Cancer Res 1996; 56:1746-1750.
13. Ohnuma T, Holland JF, Masuda H, Waligunda JA, Goldberg GA. Microbiological assay of bleomycin: inactivation, tissue distribution, and clearance. Cancer 1974; 33:1230-1238.
14. Filderman AE, Genovese LA, Lazo JS. Alterations in pulmonary protective enzymes following systemic bleomycin treatment in mice. Biochem Pharmacol 1988; 37:1111-1116.
15. Lazo JS, Humphreys CJ. Lack of metabolism as the biochemical basis of bleomycin-induced pulmonary toxicity. Proc Natl Acad Sci USA 1983; 80:3064-3068.
16. Haston CK, Wang M, Dejournett RE, Zhou X, Ni D, Gu X, et al. Bleomycin hydrolase and a genetic locus within the MHC affect risk for pulmonary fibrosis in mice. Hum Mol Genet 2002; 11:1855-1863.
17. Schwarte DR, Homanics GE, Hoyt DG, Klein E, Abernethy J, Lazo JS. The neutral cysteine protease bleomycin hydrolase is essential for epidermal integrity and bleomycin resistance. Proc Natl Acad Sci USA 1999; 96:4680-4685.
18. Montoya SE, Ferrell RE, Lazo JS. Genomic structure and genetic mapping of the human neutral cysteine protease bleomycin hydrolase. Cancer Res 1997; 57:4191-4195.
19. Koldamova RP, Leflerov IM, Gadjeva VG, Lazo JS. Essential binding and functional domains of human bleomycin hydrolase. Biochemistry 1998; 37:2282-2290.
20. Sleijfer S, van der Mark TW, Schraffordt Koops H, Mulder NH. Decrease in pulmonary function during bleomycin-containing combination chemotherapy for testicular cancer: not only a bleomycin effect. Br J Cancer 1995; 71:120-123.
21. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16:1215.
22. Rae JM, Cordero KE, Scheys JO, Lippman ME, Flockhart DA, Johnson MD. Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples. Pharmacogenetics 2003; 13:501-507.
23. Tuimala J, Szekely G, Gundy S, Hirvonen A, Norppa H. Genetic polymorphisms of DNA repair and xenobiotic-metabolizing enzymes: role in mutagen sensitivity. Carcinogenesis 2002; 23:1003-1008.
24. Levi JA, Raghavan D, Harvey V, Thompson D, Sandeman T, Gill G, et al. The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. J Clin Oncol 1993; 11:1300-1305.
25. Montoya SE, Aston CE, DeKosky ST, Kamboh MI, Lazo JS, Ferrell RE. Bleomycin hydrolase is associated with risk of sporadic Alzheimer's disease. Nat Genet 1998; 18:211-212.
26. Namba Y, Ouchi Y, Asada T, Hattori H, Ueki A, Ikeda K. Lack of association between bleomycin hydrolase gene polymorphism and Alzheimer's disease in Japanese people. Ann Neurol 1999; 46:136-137.
27. Fairer LA, Abraham CR, Haines JL, Rogaeva EA, Song Y, McGraw WT, et al. Association between bleomycin hydrolase and Alzheimer's disease in caucasians. Ann Neurol 1998; 44:808-811.
28. Sleijfer S, van der Mark TW, Schraffordt Koops H, Mulder NH. Enhanced effects of bleomycin on pulmonary function disturbances in patients with decreased renal function due to cisplatin. Eur J Cancer 1996; 32:550-552.
29. Dorr RT. Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics. Semin Oncol 1992; 19:3-8.
30. Crooke ST, Comis RL, Einhorn LH, Strong JE, Broughton A, Prestayko AW. Effects of variations in renal function on the clinical pharmacology of bleomycin administered as an iv bolus. Cancer Treat Rep 1977; 61:1631-1636.
31. Collis C. Lung damage of cytotoxic drugs. Cancer Chemother Pharmacol 1980; 4:17-27.
32. Einhorn LH, Williams SD, Loehrer PJ, Birch R, Drasga R, Omura G, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol 1989; 7:387-391.